Modelling the economic and health consequences of cardiac resynchronization therapy in the UK
暂无分享,去创建一个
Alexandra Ward | A. Ward | F. Leyva | J. Jaime Caro | Shien Guo | S. Chalil | Farzana Malik | J. Jaime Caro | Francisco Leyva | Shajil Chalil | Shien Guo | Farzana Malik
[1] Randall P. Sadowski,et al. Simulation with Arena , 1998 .
[2] J. Daubert,et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.
[3] D. Kass,et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. , 2005, Journal of the American College of Cardiology.
[4] Thomas Lavergne,et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. , 2002, Journal of the American College of Cardiology.
[5] S. Brailsford,et al. The evaluation of screening policies for diabetic retinopathy using simulation , 2002, Diabetic medicine : a journal of the British Diabetic Association.
[6] D. DeMets,et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.
[7] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[8] Salim Yusuf,et al. Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.
[9] Stefan Sack,et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. , 2002, Journal of the American College of Cardiology.
[10] L. Stevenson,et al. Preferences for quality of life or survival expressed by patients with heart failure. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[11] N Freemantle,et al. The CARE‐HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end‐points , 2001, European journal of heart failure.
[12] J. Fleg,et al. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. , 2006, American heart journal.
[13] Anthony J Culyer,et al. National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.
[14] P. Dolan,et al. Modeling valuations for EuroQol health states. , 1997, Medical care.
[15] Nick Freemantle,et al. The impact of chronic heart failure on health‐related quality of life data acquired in the baseline phase of the CARE‐HF study , 2005, European journal of heart failure.
[16] W. V. D. van den Heuvel,et al. Psychometric properties of the Minnesota Living with Heart Failure Questionnaire (MLHF-Q) , 2001, Clinical rehabilitation.
[17] J. Daubert,et al. Baseline characteristics of patients recruited into the CARE‐HF study , 2005, European journal of heart failure.
[18] D. Delurgio,et al. Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.
[19] M. Tabberer,et al. Economic burden of post‐acute myocardial infarction heart failure in the United Kingdom , 2005, European journal of heart failure.
[20] L. Rydén,et al. Reduction of hospital days by biventricular pacing , 2000, European journal of heart failure.
[21] Ruth Davies,et al. The Development of a Simulation Model of the Treatment of Coronary Heart Disease , 2002, Health care management science.
[22] J. Cohn,et al. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. , 1992, American heart journal.
[23] Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. , 2005 .
[24] Sally C Morton,et al. A model for a smallpox-vaccination policy. , 2003, The New England journal of medicine.
[25] J. Ornato,et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .
[26] J. Daubert,et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. , 2006, European heart journal.
[27] J. Peters,et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) , 2006, Current medical research and opinion.
[28] Milton Packer,et al. Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.
[29] Craig J Currie,et al. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. , 2005, Clinical therapeutics.
[30] K. Banz. Cardiac resynchronization therapy ( CRT ) in heart failure : a model to assess the economic value of this new medical technology , 2019 .